Keybank National Association OH Sells 5,109 Shares of GlaxoSmithKline plc (NYSE:GSK)

Keybank National Association OH decreased its position in GlaxoSmithKline plc (NYSE:GSK) by 7.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 60,920 shares of the pharmaceutical company’s stock after selling 5,109 shares during the quarter. Keybank National Association OH’s holdings in GlaxoSmithKline were worth $2,600,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in GSK. Jane Street Group LLC increased its stake in GlaxoSmithKline by 7,574.0% in the 2nd quarter. Jane Street Group LLC now owns 1,816,424 shares of the pharmaceutical company’s stock worth $72,693,000 after acquiring an additional 1,792,754 shares during the last quarter. Fisher Asset Management LLC increased its stake in GlaxoSmithKline by 10.2% in the 3rd quarter. Fisher Asset Management LLC now owns 15,267,588 shares of the pharmaceutical company’s stock worth $651,621,000 after acquiring an additional 1,412,368 shares during the last quarter. Renaissance Technologies LLC increased its stake in GlaxoSmithKline by 6.9% in the 2nd quarter. Renaissance Technologies LLC now owns 15,261,781 shares of the pharmaceutical company’s stock worth $610,776,000 after acquiring an additional 989,181 shares during the last quarter. Point72 Asset Management L.P. increased its stake in GlaxoSmithKline by 362.1% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,105,172 shares of the pharmaceutical company’s stock worth $44,229,000 after acquiring an additional 866,015 shares during the last quarter. Finally, Invesco Ltd. increased its stake in GlaxoSmithKline by 502.4% in the 2nd quarter. Invesco Ltd. now owns 644,331 shares of the pharmaceutical company’s stock worth $25,786,000 after acquiring an additional 537,370 shares during the last quarter. 11.19% of the stock is currently owned by institutional investors and hedge funds.

In related news, Director Plc Glaxosmithkline bought 177,777 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were purchased at an average price of $45.00 per share, with a total value of $7,999,965.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 10.00% of the company’s stock.

Shares of NYSE GSK traded up $0.21 during trading hours on Friday, hitting $44.42. 1,985,586 shares of the company traded hands, compared to its average volume of 2,550,711. The stock has a market capitalization of $110.42 billion, a price-to-earnings ratio of 14.06, a price-to-earnings-growth ratio of 3.03 and a beta of 0.70. The company has a current ratio of 0.82, a quick ratio of 0.56 and a debt-to-equity ratio of 1.38. The company’s 50 day moving average price is $42.96 and its 200 day moving average price is $41.12. GlaxoSmithKline plc has a 12 month low of $36.41 and a 12 month high of $46.01.

GlaxoSmithKline (NYSE:GSK) last released its earnings results on Wednesday, October 30th. The pharmaceutical company reported $0.95 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $0.10. The firm had revenue of $11.57 billion for the quarter, compared to the consensus estimate of $11.34 billion. GlaxoSmithKline had a return on equity of 92.73% and a net margin of 13.76%. Equities analysts anticipate that GlaxoSmithKline plc will post 3.08 EPS for the current year.

A number of research firms have issued reports on GSK. Deutsche Bank reaffirmed a “hold” rating on shares of GlaxoSmithKline in a research note on Thursday, October 31st. Cantor Fitzgerald raised GlaxoSmithKline from a “hold” rating to a “buy” rating in a research report on Friday, October 11th. UBS Group reissued a “neutral” rating on shares of GlaxoSmithKline in a research report on Wednesday, October 23rd. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a research report on Thursday, October 17th. Finally, Goldman Sachs Group reissued a “buy” rating on shares of GlaxoSmithKline in a research report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $41.79.

GlaxoSmithKline Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Read More: Leveraged Buyout (LBO)

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.